Medicinski Glasnik (Feb 2011)

Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina

  • Sabina Semiz,
  • Tanja Dujić,
  • Barbara Ostanek,
  • Besim Prnjavorac,
  • Tamer Bego,
  • Maja Malenica,
  • Barbara Mlinar,
  • Janja Marc,
  • Adlija Čaušević

Journal volume & issue
Vol. 8, no. 1
pp. 84 – 89

Abstract

Read online

Aim Differences in the frequency of distribution of the cytochromeP450 (CYP) allelic variants have been demonstrated between distinct ethnic groups, contributing to observed interindividual variation in drug response. In this study we determined, for the irst time, prevalence of the common allelic variants of the polymorphic CYP enzymes, CYP3A4*1B and CYP3A5*3, in the population of Bosnia and Herzegovina (BH). Methods Genomic DNA was extracted from blood samples collected from 140 unrelated subjects. A real-time PCR was used for the detection of CYP polymorphisms, with the application of the speciic TaqMan® SNP Genotyping Assay (Applied Biosystems)for CYP3A5*3, while CYP3A4*1B was genotyped by high-resolution melting analysis. Results Our results have shown that the distribution of CYP3A4*1B and CYP3A5*3 alleles was in line with the data reported in European Caucasians. We conirmed that CYP3A4*1B mutant allele is rare in Caucasians, being present in only 5.1% individuals. However, CYP3A5*3 polymorphism was found to be predominant in the Bosnian population with an incidence of 94%, similarly to other European populations tested so far. Interestingly, we have demonstrated a strong linkage disequilibrium between CYP3A5*3 and CYP3A4*1B alleles. No signiicant difference in allele frequencies for CYP3A4*1B and CYP3A5*3 has been shown between male and female subjects participating in our study. Conclusion Our data demonstrated the high prevalence of CYP3A5*3 allele in Bosnian population, indicating signiicance of analysis of CYP3A5 and CYP3A4 polymorphisms and corresponding allele frequencies in speciic ethnic groups. Importantly, results of this study may lead to translation of pharmacogenetics and individualized therapeutic approach in current clinical practices in BH.

Keywords